Prima RNApols Enable mRNA Manufacturing For RNA-Based Vaccines And Therapeutics

The standard reliance on T7 RNA polymerase for mRNA manufacturing often creates bottlenecks, particularly when scaling the production of long, complex sequences for vaccines and therapeutics. Traditional methods frequently struggle with diminished integrity for RNAs exceeding 10 kb and the high costs associated with massive DNA template requirements. By utilizing a diverse panel of evolved, customizable enzymes, manufacturers can achieve significantly higher yields while using up to 10 times less DNA template.

This shift not only lowers reaction costs but also minimizes unwanted side products like double-stranded RNA. With improved capping efficiency and compatibility with various nucleotide chemistries, these advanced polymerases ensure high-integrity, full-length sequences.

Explore this infographic to see how evolved enzymes optimize RNA production workflows.